Karthik Venkatakrishnan

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Neeraj Gupta, M. Hanley, K. Yeo, 2024, CPT: pharmacometrics & systems pharmacology.

Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma

Akash Khandelwal, J. Hibma, Karthik Venkatakrishnan, 2024, Clinical and translational science.

Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

Jonathan L French, Ramon Garcia, Karthik Venkatakrishnan, 2023, CPT: pharmacometrics & systems pharmacology.

Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments

E. Kleinerman, C. Oliva, P. Meyers, 2014, Pediatric blood & cancer.

Model-informed Evidence for Clinical Non-inferiority of Every-2-Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer.

S. Hayes, Ana-Marija Milenković-Grišić, Karthik Venkatakrishnan, 2024, Clinical pharmacology and therapeutics.

Explainable machine learning prediction of edema adverse events in patients treated with tepotinib

N. Terranova, Federico Amato, Karthik Venkatakrishnan, 2024, Clinical and translational science.

Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

Ö. Yalkinoglu, S. Gopalakrishnan, Karthik Venkatakrishnan, 2024, Clinical pharmacology and therapeutics.

Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler

J. Bolleddula, N. Terranova, J. Mukker, 2024, Clinical and translational science.